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1
 Abstract 
 
Background The degree of inflammatory response with cytokine release is associated with poor outcome after 
aneurysmal subarachnoid hemorrhage (SAH). Previously, we reported about an association between systemic 
IL-6 levels and clinical outcome in patients with aneurysmal subarachnoid hemorrhage (SAH). The intention 
was to assess the impact of nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen on the 
inflammatory response after SAH. 
 
Methods Exploratory analysis of data and samples collected within a previous study. In 138 patients with SAH 
systemic interleukin (IL)-6 and c-reactive protein (CRP) were measured daily up to day 14 after SAH. The 
correlations between the cumulatively applied amount of NSAIDs, inflammatory parameters as well as clinical 
outcome were calculated. 
 
Results An inverse correlation between cumulatively applied NSAIDs and both IL-6 and CRP levels was found 
(r=-0.437, p<0.001 and r=-0.369, p<0.001 respectively). Multivariable linear regression analysis showed 
cumulative amount of NSAIDs to be independently predictive for systemic IL-6 and CRP levels. The cumulative 
amount of NSAIDs reduced the odds for unfavorable outcome, defined as Glasgow outcome scale 1-3. 
 
Conclusions The results indicate a potential beneficial effect of NSAIDs in patients with SAH in terms of 
ameliorating inflammatory response, which might have an impact on outcome. 
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 Introduction 
 
Considerable advances in diagnosis, surgical treatment and neurocritical care medicine have reduced the risk 
of mortality after aneurysmal subarachnoid hemorrhage (SAH). However the functional outcome remains poor 
in these patients [1]. Ample evidence derived from experimental settings suggests that inflammatory pathways 
with cytokine release, such as interleukin-6 (IL-6), are involved in the pathogenesis of cerebral injury [2-4]. 
Recently, we reported about a positive correlation between systemic IL-6 levels and poor outcome in patients 
with SAH [5]. Several drugs, including nonsteroidal anti-inflammatory drugs (NSAIDs), aimed at limiting the 
inflammatory response, have been experimentally validated, with varying levels of success [2, 6-11]. However, 
clinical studies specifically examining the effect of NSAIDs on inflammatory response and outcome after SAH 
are virtually nonexistent. The present study intended to elucidate the potential impact of NSAID application -
including acetaminophen- on inflammatory parameters -in particular IL-6 levels- in the acute phase after SAH 
[5]. 
 
 
Materials and Methods 
 
The current study is an exploratory analysis of data and samples collected within a previous study [5]. In 
brief, the prospective observational study was carried out at a single academic tertiary care center during a 3-
years period. Because of its purely exploratory design, a sample size calculation was not determined. The study 
was approved by the local ethics committee. All patients with confirmed aneurysmal SAH were included. The 
diagnosis was based on CT and angiography studies. Exclusion criteria included admission >3 days after ictus, 
uncertain time of ictus, death within 3 days after admission, and conservative or delayed aneurysm treatment. 
The severity at time of admission was assessed based on the World Federation of Neurological Surgeons 
(WFNS) grading. All patients were treated according to a standardized treatment protocol as previously 
described [5, 12-14]. In all patients, mean arterial blood pressure (MAP) was monitored by an arterial catheter. 
MAP was held constant within the range of 80-120 mmHg after aneurysm securement. Blood glucose 
concentration was measured at least q 4 hours and was held constant within the range of 5-8 mmol/ml. In 
intubated and ventilated patients, arterial pO2 and pCO2 was measured at least q 4 hours and kept within 
following range: paO2: >12.0 kPa and pCO2: 4.8-5.6 kPa. The duration of sedation was kept as short as possible. 
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 Indications for long-term sedation are intracranial hypertension and/or severe cardiac or respiratory failure. Core 
body temperature ≥38° C was regarded as fever, and was treated accordingly. NSAID prescription in general 
was at the discretion of the attending neurointensivist on duty, based on a stepwise management scheme starting 
with acetaminophen (INN, paracetamol) followed by dipyrone (INN, metamizol), diclofenac and ibuprofen. 
Contraindication for acetaminophen was pathologically high lever enzymes. Known ulcer diseases, erosive 
gastritis or colitis, coagulation disorders and unsecured aneurysms were contraindications for ibuprofen and 
diclofenac. Dosages were adapted to body weight and kidney function. Maximum dosages per day were 4g for 
acetaminophen, 4g for dipyrone, 150mg for diclofenac and 2.4g for ibuprofen. As for inflammatory parameter, 
daily systemic c-reactive protein (CRP) and interleukin-6 (IL-6) levels were measured in terms of clinical 
routine from day 3 to 14 after SAH. Physiological IL-6 and CRP levels are <3.3 ng/l and <5 mg/l respectively. 
Blood sampling was performed in the early morning between 06:30 and 07:30 hours. The samples underwent no 
freeze-thaw cycle, as the samples were analyzed once, immediately by the Institute of Clinical Chemistry, 
University Hospital Zurich. IL-6 and CRP levels were not integral part of the NSAID management scheme. The 
principal investigator (C.M.) was not a treating physician, and did not have any influence on NSAID 
prescription.  
Infectious complications were assessed as confounding factors, as they influence the level of inflammatory 
parameters [15]. Criteria for the presence of an infectious complication are summarized in Table 1. Having a 
potential impact on inflammatory serum parameters as well as on prescription of NSAIDs, the application of 
mild therapeutic hypothermia (intravascular catheter-based heat exchange system, Zoll Medical, Chelmsford, 
MA, USA; target brain temperature 33-34° C) was also included in the analysis. Indications for hypothermia 
included elevated intracranial pressure and/or symptomatic CVS refractory to conventional treatment [16]. 
Having a direct impact on outcome, the occurrence of cerebral infarction was assessed as a confounding factor 
[17]. Cerebral infarction was defined as new ischemic lesions, which could not be attributed to surgery or 
endovascular intervention. All patients had a baseline cranial computed tomography. Further scans were 
obtained within 24 hours after the aneurysm-securing procedure, at discharge, and if the patient had neurological 
worsening. The clinical outcome was assessed 3 months after SAH in the outpatient clinic, based on the 
Glasgow outcome scale (GOS). 
Categorical variables were described using frequency and percentage. WFNS grades were dichotomized into 
non-severe (WFNS 1-3) and severe (WFNS 4-5), GOS scales into unfavorable (GOS 1-3) and favorable (GOS 4-
5). Continuous variables were described as median and quartiles if not otherwise indicated. As IL-6 and CRP 
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 levels showed a high variance, the values were logarithmically transformed for statistical analysis. A variable 
“cumulative NSAID days” was defined for semi-quantification and represents the sum of days (until day 14 after 
SAH), where the patients received NSAID, multiplied by the number of different NSAIDs including 
acetaminophen. This methodological simplification was performed as quantitative equivalent conversion is not 
possible for NSAIDs. Occurrence of fever was quantified as febrile days, defined as exceeding threshold core 
body temperature ≥38° C for >1 hour at least once per day. 
Pearson’s correlation coefficient between median values of inflammatory markers and cumulative NSAID 
days was calculated. A linear regression analysis was performed to assess the effect of NSAIDs on inflammatory 
parameters unadjusted and adjusted for confounding variables. Application of therapeutic hypothermia, WFNS 
grade, occurrence of infectious complications and occurrence of fever were considered as possible confounding 
factors. The correlation between NSAID days and binominal variables was calculated by a point-biserial 
correlation analysis. To investigate whether application of NSAIDs had an impact on outcome an unconditional 
logistic regression, unadjusted and adjusted for confounding covariates, was performed. Age, WFNS grade, 
occurrence of cerebral infarctions and fever were defined as confounding factors, representing generally 
accepted, clinically meaningful predictors in patients with SAH [17-20]. For the significant factors, odds ratios 
(OR) and their 95% confidence intervals (CI) were calculated. A p-value <0.05 was regarded as statistically 
significant. IBM SPSS Statistics 20.0 Software was used. 
 
 
Results 
 
Of the 209 patients with SAH admitted to the Neurocritical Care Unit, University Hospital of Zurich, during 
the 3-year period, 138 patients were analyzed in the present study. Exclusion criteria were met in 71 patients. 
The patients’ characteristics are shown in Table 2. Fifty patients (36%) received 2, 38 patients (28%) received 3 
and 12 patients (9%) received 4 different types of NSAIDs. Eleven patients (8%) received 1 single type NSAID. 
The most frequent NSAID was acetaminophen followed by dipyrone, diclofenac and ibuprofen. Overall median 
cumulative NSAID days was 15.5 (range 0-42), 20 (range 0-42) in patients without and 2 (range 0-19) in 
patients with therapeutic hypothermia. The difference was statistically highly significant (p<0.001, Mann-
Whitney test). In the majority of these cases application of NSAIDs decreased dramatically, as soon as the target 
temperature was achieved and maintained. Quantitatively, an inverse correlation could be found between 
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 cumulative NSAID days and number of days with hypothermia (r=-0.677, p<0.001). The analysis of the 
correlation between cumulative NSAID days and IL-6 established an inverse correlation (r=-0.437, p<0.001) 
(Fig. 1A). Furthermore, there also was a weaker inverse correlation between the cumulative NSAID days and 
CRP (r=-0.369, p<0.001) (Fig. 1B). A subgroup analysis showed a correlation in patients without hypothermia 
(r=-0.504; p<0.001 for IL-6 and r=-0.326; p<0.001 for CRP respectively), while no correlations could be found 
in patients with hypothermia. Due to the weaker anti-inflammatory properties of acetaminophen, a sub-analysis 
was performed without acetaminophen: The correlation between cumulative NSAID days (without 
acetaminophen) and IL-6 and CRP was r=-0.409, p<0.001 and r=-0.327, p<0.001 respectively. The correlations 
were weaker than with acetaminophen. A weak positive correlation between IL-6 and number of febrile days 
was found (r=0.198, p=0.02), while correlation between CRP and number of febrile days could not be found 
(r=0.134, p=0.12). The partial correlation coefficient between cumulative NSAID days and IL-6/CRP, adjusted 
for febrile days, was stronger than the previous unadjusted coefficients (r=-0.484, p<0.001 for IL-6 and r=-
0.400, p<0.001 for CRP respectively). Analyzing the correlation between occurrence of cerebral infarction and 
cumulative NSAID days, a weak inverse correlation was found (r=-0.222, p<0.010). A moderate inverse 
correlation was found between cumulative NSAID days and dichotomized outcome (r=-0.365; p<0.001). This 
correlation remained present after exclusion of patients receiving therapeutic hypothermia (r=-0.244, p=0.013). 
We also found an inverse correlation between WFNS grade and cumulative NSAID days (r=-0.409; p<0.001). 
As shown in Table 3, linear regression analysis showed cumulative NSAID days to be predictive for systemic 
IL-6 and CRP levels in an inverse manner, unadjusted and adjusted for confounding factors. In the logistic 
regression analysis the variable cumulative NSAID days revealed to be an inverse predictor for poor outcome 
(GOS 1-3): OR 0.918 (95% CI: 0.880-0.956, p<0.001). After exclusion of patients receiving therapeutic 
hypothermia, the variable cumulative NSAID remained an inverse predictor for poor outcome: OR 0.932 (95% 
CI: 0.881-0.897, p=0.016). After adjustment for confounding factors (WFNS grade, occurrence of cerebral 
infarction, age, and febrile days), cumulative NSAID days remained an independent inverse predictor for poor 
outcome: OR 0.921 (95% CI: 0.870-0.975, p=0.005). The inclusion of aneurysm treatment modality in the 
regression analyses did not alter the result. The adjusted odds ratios are shown in Table 4. Logistic regression 
analysis showed the variable cumulative NSAID days to be an inverse predictor for the occurrence of cerebral 
infarction as well: OR 0.933 (95% CI: 0.884-0.986, p=0.013). 
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 Discussion 
 
The present study established an inverse relationship between the amount of NSAIDs applied and systemic 
inflammatory parameters (IL-6 and CRP) in the acute phase (≤ day 14) after SAH. Linear regression analysis 
showed, that the amount of NSAIDs applied was predictive for lower IL-6 and CRP levels after adjustment for 
potentially confounding factors. These results are of interest, as high CRP and IL-6 levels in particular have been 
associated with worse neurological outcome in patients with SAH [3, 5, 21]. In the logistic regression analysis, 
the cumulative amount of NSAIDs reduced the odds for worse functional outcome. Although the occurrence of 
fever was correlated to some extent, the effect of NSAIDs on as well inflammatory markers as neurological 
outcome could not be attributed to the effect of fever alone in our statistical model. While age, severity of SAH 
and occurrence of cerebral infarction are well-accepted risk factors for worse outcome [18, 19], the relation 
between NSAID application and outcome is a rather new aspect. This positive impact on the outcome might be 
partially related to the decrease in the occurrence of cerebral infarctions as. However, based on the multivariable 
regression analysis, NSAID acts beneficial independently from its ability to avoid the occurrence of cerebral 
infarctions.  
An additional observation of interest is the influence of the application of therapeutic hypothermia on the 
prescription of NSAIDs. The prescription of NSAIDs decreased dramatically as soon as therapeutic hypothermia 
was induced. Although induction and maintenance of hypothermia were strictly based on a protocol [14], we 
were not consciously aware of the fact that the application of hypothermia led to a decreased prescription of 
NSAIDs, as this aspect was not considered in the protocol up to date. 
Classical NSAIDs applied in the current patient population are diclofenac and ibuprofen, both unselective 
COX inhibitors. They mainly exert their anti-inflammatory and analgesic properties by inhibiting the 
cyclooxygenase (COX)-2 pathway. COX-2 enzymes synthesize proinflammatory prostaglandins (PG). However, 
they also have an inhibitory effect on COX-1, which is constitutively expressed in platelets and is responsible for 
the formation of pro-aggregatory thromboxane A2. Acetaminophen is often claimed to posses no or only weak 
anti-inflammatory properties. Therefore, it is generally not considered as a NSAID. However, it is noteworthy 
that this statement is based largely on early works showing that acetaminophen does not suppress inflammation 
associated with rheumatoid arthritis, whereas anti-inflammatory action has been supported in different types of 
inflammatory conditions and the mechanism of action has been suggested to be its highly selective COX-2 
inhibition [22]. A more contemporary study suggests a reinvestigation of acetaminophen in terms of anti-
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 inflammatory mechanisms [22]. Furthermore, the drug has always been associated with a suppression of PG 
synthesis in the CNS [22]. Based on our results, it might be assumed that acetaminophen has some effect on the 
inflammatory response, as the correlations of cumulative NSAID days with IL-6 and CRP were weaker without 
acetaminophen. Another NSAID drug that was included in the analysis was dipyrone, which has pronounced 
analgesic and antipyretic effects, but weak anti-inflammatory effects as well [23]. Although its mechanism of 
action is not entirely clear, it elicits substantial inhibition of COX in humans. With respect to the COX 
inhibition, NSAIDs are reported to act via other mechanisms such as inhibition of leukocyte-endothelial cell 
interaction or modulation of cytokine expressions, including IL-6 [24, 25]. 
Due to the potential inhibitory effect on platelet aggregation, some neurosurgeons and neurointensivists 
might be reluctant to apply NSAIDs for analgesic and antipyretic purposes after SAH [26-28]. However, there is 
no evidence that administration of NSAIDs carries a higher risk for rebleeding and consecutive worse outcome. 
In the current study no intracranial rebleedings attributable to excessive NSAIDs application could be identified. 
On the one hand there are virtually no consensus and guidelines with regard to pain management and application 
of NSAIDs [26-28]. On the other hand, according to the international multidisciplinary consensus conference on 
the critical care management of subarachnoid hemorrhage, the application of NSAIDs is considered to be the 
first-line intervention in order to control hyperthermia [20]. There is certainly a strong rationale to avoid fever, 
as it has been repeatedly connected to worse outcome [20]. As central thermoregulation might be hampered after 
SAH, NSAIDs might not be effective enough tough. Advanced temperature controlling using cooling devices - 
cooling blankets or an intravascular heat exchange catheter - might be more effective in these cases. More 
recently, Broessner et al. compared the effectiveness of endovascular cooling to maintain normothermia with 
standardized, stepwise, escalating fever management in patients with ischemic or hemorrhagic stroke: Long-
term, catheter-based, prophylactic normothermia significantly reduced fever burden [29]. Interestingly, CRP and 
IL-6 levels were significantly higher, while the application of NSAIDs was significantly lower in the device 
group compared to the controls. A subgroup analysis revealed that application of NSAIDs led to a significant 
decrease of CRP in patients with endovascular cooling. The authors argued that the combination of advanced 
temperature controlling with NSAIDs might have additional neuroprotective effects [30]. This has yet to be 
proven. 
There is increasing evidence that the degree of inflammatory response is associated with occurrence of 
secondary ischemic events and/or worse outcome after SAH [2, 3, 5]. Therefore, there is a strong rationale to 
suppress inflammatory response. In animal experimental studies, NSAIDs have been shown to prevent CVS or 
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 brain edema after SAH, either by COX-inhibition or other mechanisms such as inhibition of leukocyte-
endothelial cell interactions [6-8, 10, 31, 32], while dipyrone has been found to be remarkably neuroprotective in 
experimental cerebral ischemia [33]. 
In theory, the potential inhibitory effect of NSAIDs on platelet aggregation might act beneficial too as 
activation of the coagulation cascade and occurrence of microthrombosis has been discussed to contribute to the 
pathogenesis of cerebral infarction [34]. Clinical studies with antiplatelet therapies showed a trend towards 
improved outcome. However, no definite conclusions could be drawn. On the basis of the current evidence, 
routine treatment with antiplatelet agents in order to prevent cerebral infarction or poor outcome is currently not 
recommended [35]. There are virtually no clinical trials specifically aimed to investigate the role of NSAID on 
inflammatory response in patients with SAH. To the best to our knowledge, only acetylic-acid (ASA) - an 
NSAID with irreversible COX-inhibition - has been clinically evaluated in a controlled randomized trial. 
However, the trial was conducted with the anti-aggregatory effect of ASA in mind, and not with regard to its 
anti-inflammatory effect. The trial did not confirm a beneficial effect of rectal ASA administration on the 
occurrence of delayed ischemic neurological deficit. However, functional outcome in patients who received 
ASA tended to be better [36]. 
Hypothermia might exert its neuroprotective properties by attenuation of destructive inflammatory reactions. 
Mild hypothermia has been shown to reduce proinflammatory cytokine levels such as IL-6 after different types 
of brain insults, including SAH [16, 37, 38]. As patients with therapeutic hypothermia need deep analgosedation, 
there might be no objective to administer NSAIDs for fever and pain management. However, the combination of 
NSAIDs and mild hypothermia might have synergistic anti-inflammatory and neuroprotective effects. This calls 
for further examinations, as the answer to the latter question is beyond the possibilities of the present study due 
to its limited sample size and observational nature. 
A clear shortcoming of the current study is the fact, that different types of NSAIDs were lumped together for 
analysis, despite their different anti-inflammatory potencies. However, this methodological simplification was 
performed as quantitative equivalent conversion is not possible, in contrast to corticosteroids. A separated 
subanalysis for each medication was regarded as questionable as all medication was applied in a stepwise 
management scheme. Further, the drugs mentioned were used not only as antipyretics, but for pain treatment as 
well, and the detailed discrimination between the two indications could not be performed due to methodological 
reasons. Patient with better level of consciousness would be expected to both need more painkillers and have 
better outcome than patients in coma. The inverse correlation between WFNS grade and cumulative amount of 
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 NSAIDs we found supports this assumption. However, based on the results of the regression analysis, amount of 
NSAIDs remained an independent predictor for poor outcome. It also has to be mentioned, that the pre-
determined exclusion criteria might have biased the current results [5]. Another shortcoming is the fact that only 
systemic inflammatory markers were measured. It would be of great interest to additionally measure intrathecal 
inflammatory markers to assess the impact of NSAIDs, with or without hypothermia, on the compartmental 
inflammatory response within the CNS. Finally, the actual mechanism by which NSAIDs influenced both 
inflammatory parameters and outcome cannot be answered. 
 
 
Conclusions 
 
The results of the current study indicate an inverse correlation between the amounts of NSAIDs applied and 
systemic IL-6 and CRP levels in patients with SAH. A higher amount of NSAID application reduced the odds 
for unfavorable outcome. In the present study therapeutic hypothermia led to a significant decrease of NSAID 
application. In case of using cooling devices to induce normo- or hypothermia, the question arises whether to 
continue with NSAID application or not, as it might act synergistic in terms of ameliorating inflammation. 
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Figure legend 
 
Fig 1 Inverse correlations of cumulative NSAID days and log IL-6 A) and CRP B) shown as scatterplots. A) 
Pearsons’ correlation r=-0.437 (p<0.001) and B) r=-0.369 (p<0.001). 
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Table 1 Criteria for infectious complications 
      
   
Pneumonia  Specific signs of alveolar infiltrate on chest x-ray and microorganism 
isolated from tracheobronchial secretion cultures* 
   
Blood stream infection  Predominant microorganism identified in blood cultures* 
   
Urinary tract infection  Isolation of >10
5
 microorganisms/ml in urinary cultures* 
   
Catheter-related infection  Isolation of >10
5
 colony-forming units from catheter tips* 
   
CSF infection  Pleocytosis with positive microbiological cultures 
      
   
CSF cerebrospinal fluid, * cultures were only obtained in the setting of suspected infection. 
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Table 2 Patients' characteristics 
  
 
  Total (n=138) 
    
    
Age, y, mean ±SD 55.3 ± 12.9 
    
Sex   
 Female, n (%) 91 (66%) 
 Male, n (%) 47 (34%) 
    
WFNS Grade   
 1-3, n (%) 91 (66%) 
 4-5, n (%) 47 (34%) 
    
Aneurysm treatment   
 Clipping 78 (56%) 
 Coiling 60 (44%) 
    
Temp. ≥38°C, days, median (range) 2.54 (0-10) 
    
Therapeutic hypothermia   
 No hypothermia, n (%) 103 (75%) 
 Hypothermia, n (%) 35 (25%) 
    
Infectious complications   
 No infection 63 (46%) 
 Infection 75 (54%) 
    
Cerebral infarction   
 Cerebral infarction 19 (14%) 
 No cerebral infarction 115 (85%) 
    
Outcome (GOS)   
 Favorable (GOS 4-5), n (%) 94 (68%) 
 Unfavorable (GOS 1-3), n (%) 44 (32%) 
    
Inflammatory Parameter   
 IL-6, ng/l, median (Q1; Q3) 7.7 (4.2; 13.8) 
 CRP, mg/l, median (Q1; Q3) 23 (12; 40) 
 
 
SD standard deviation, Temp.core body temperature, Q1 under quartile, Q3 
upper quartile. 
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Table 4 logistic regression analysis for unfavorable outcome 
 OR 95% CI Sig. 
  Upper Lower  
Cummulative NSAID days 0.924 0.873 0.979 p=0.007 
Age (years) 1.055 1.014 1.098 p=0.008 
Febrile days 1.007 0.85 1.194 p=0.935 
WFNS 1-3 Reference category 
WFNS 4-5 0.321 0.122 0.846 p=0.022 
No cerebral infarction Reference category 
Cerebral infarction 0.348 0.112 1.077 p=0.067 
Coiling Reference category 
Clipping 0.582 0.241 1.403 p=0.228 
OR (adjusted) odds ratio, CI confidence interval, Sig significance.  
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Figure 1
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